Blood Cancer Journal最新文献_第3页

A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study. 转化的惰性淋巴瘤和新生弥漫性大b细胞淋巴瘤的比较分析：一项基于人群的队列研究。

IF 12.9 1区医学

Blood Cancer Journal Pub Date : 2024-11-29 DOI: 10.1038/s41408-024-01194-5

John L Vaughn, Angela Ramdhanny, Malak Munir, Sravani Rimmalapudi, Narendranath Epperla

{"title":"A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study.","authors":"John L Vaughn, Angela Ramdhanny, Malak Munir, Sravani Rimmalapudi, Narendranath Epperla","doi":"10.1038/s41408-024-01194-5","DOIUrl":"10.1038/s41408-024-01194-5","url":null,"abstract":"Histologic transformation (HT) of indolent non-Hodgkin lymphoma (iNHL) to diffuse large B-cell lymphoma (DLBCL) carries a poor prognosis. Using the Surveillance, Epidemiology, and End Results-17 database, we conducted a population-based study of adult patients with transformed follicular lymphoma (t-FL), marginal zone lymphoma (t-MZL), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (t-LPL/WM), and de novo DLBCL. Primary outcome was relative survival (RS), and secondary outcomes included overall survival (OS) and lymphoma-specific survival (LSS). Outcomes were modeled using flexible parametric survival models, while multivariable modeling was used to compare RS, OS, and LSS. The incidence of HT was highest in splenic MZL (SMZL, 6.78%) and lowest in extranodal MZL (EMZL, 1.62%). Median follow-up times were similar for patients with de novo DLBCL and transformed indolent lymphomas. The 5-year RS and OS were longer in de novo DLBCL compared to all other transformed iNHL subtypes (68 versus 59%, respectively). For t-FL, early transformation (within 2 years of diagnosis, Hazard ratio [HR] = 1.34) and prior treatment (HR = 1.89) were associated with inferior survival. This association was not observed in other transformed lymphoma subtypes. This is the first comparative study to show that the outcomes of t-LPL/WM were inferior compared to de novo DLBCL and highlights the need to incorporate early experimental therapies in patients with t-FL with early transformation and receipt of prior chemotherapy.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"212"},"PeriodicalIF":12.9,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11604794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis. 诊断时高水平的循环无细胞肿瘤DNA与疾病扩散相关，并定义预后不良的多发性骨髓瘤患者。

IF 12.9 1区医学

Blood Cancer Journal Pub Date : 2024-11-28 DOI: 10.1038/s41408-024-01185-6

Marina Martello, Vincenza Solli, Gaia Mazzocchetti, Antonio Giovanni Solimando, Davide Bezzi, Barbara Taurisano, Ajsi Kanapari, Andrea Poletti, Enrica Borsi, Silvia Armuzzi, Ilaria Vigliotta, Ignazia Pistis, Vanessa Desantis, Giulia Marzocchi, Ilaria Rizzello, Lucia Pantani, Katia Mancuso, Paola Tacchetti, Nicoletta Testoni, Cristina Nanni, Elena Zamagni, Michele Cavo, Carolina Terragna

{"title":"High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis.","authors":"Marina Martello, Vincenza Solli, Gaia Mazzocchetti, Antonio Giovanni Solimando, Davide Bezzi, Barbara Taurisano, Ajsi Kanapari, Andrea Poletti, Enrica Borsi, Silvia Armuzzi, Ilaria Vigliotta, Ignazia Pistis, Vanessa Desantis, Giulia Marzocchi, Ilaria Rizzello, Lucia Pantani, Katia Mancuso, Paola Tacchetti, Nicoletta Testoni, Cristina Nanni, Elena Zamagni, Michele Cavo, Carolina Terragna","doi":"10.1038/s41408-024-01185-6","DOIUrl":"10.1038/s41408-024-01185-6","url":null,"abstract":"Multiple myeloma (MM) is a plasma cell (PC) disorder characterized by skeletal involvement at the time of diagnosis. Recently, cell-free DNA (cfDNA) has been proven to recapitulate the heterogeneity of bone marrow (BM) disease. Our aim was to evaluate the prognostic role of cfDNA at diagnosis according to disease distribution, and to investigate the role of the MM microenvironment inflammatory state in supplying the release of cfDNA. A total of 162 newly diagnosed MM patients were screened using 18F-FDG PET/CT and assessed by ultra low-pass whole genome sequencing (ULP-WGS). High cfDNA tumor fraction (ctDNA) levels were correlated with different tumor mass markers, and patients with high ctDNA levels at diagnosis were more likely to present with metabolically active paraskeletal (PS) and extramedullary (EM) lesions. Moreover, we demonstrated that microenvironment cancer-associated fibroblast (CAFs)-mediated inflammation might correlate with high ctDNA levels. Indeed, a high cfDNA TF level at diagnosis predicted a poorer prognosis, independent of R-ISS III and 1q amplification; the inclusion of >12% ctDNA in the current R-ISS risk score enables a better identification of high-risk patients. ctDNA can be a reliable and less invasive marker for disease characterization, and can refine patient risk.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"208"},"PeriodicalIF":12.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11605000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. 复发或难治性弥漫性大b细胞淋巴瘤患者CAR - t细胞治疗后使用loncastuximab tesirine的结果。

IF 12.9 1区医学

Blood Cancer Journal Pub Date : 2024-11-28 DOI: 10.1038/s41408-024-01195-4

Narendranath Epperla, Melanie Lucero, Tom Bailey, Laura Mirams, Jolenta Cheung, Mona Amet, Gary Milligan, Lei Chen

{"title":"Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma.","authors":"Narendranath Epperla, Melanie Lucero, Tom Bailey, Laura Mirams, Jolenta Cheung, Mona Amet, Gary Milligan, Lei Chen","doi":"10.1038/s41408-024-01195-4","DOIUrl":"10.1038/s41408-024-01195-4","url":null,"abstract":"The efficacy of loncastuximab tesirine (lonca) following chimeric antigen receptor T-cell therapy (CAR-T) progression/failure is unknown. Hence, we sought to examine real-world use and outcomes of lonca following CAR-T in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the USA. In this retrospective study, we included adults (age ≥ 18 years) with R/R DLBCL who received lonca monotherapy as third- (3 L) or fourth line (4 L) treatment after progressing on second line (2 L) or 3 L CAR-T, respectively. Post-CAR-T lonca outcomes included response rates (overall response rate [ORR] and complete response [CR] rate), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). A total of 118 patients were included in the analysis with 95 receiving lonca following 2 L CAR-T (median age:66 years; 61% male) and 23 following 3 L CAR-T (median age:57 years; 43% male). Patients with 2 L CAR-T/3 L lonca had an ORR of 73% (CR rate of 34%). With a median follow-up of 8.5 months following lonca initiation, median DOR, PFS, and OS were not reached. The DOR, PFS, and OS at 12 months were 68%, 77%, and 84%, respectively. Patients with 3 L CAR-T/4 L lonca had an ORR of 78% (CR rate of 17%). With a median follow-up of 13 months following lonca initiation, the median DOR and PFS were 7.6 and 12.0 months, while median OS was not reached. OS at 12 months was 95%. In this study, we found that lonca monotherapy was an effective treatment option in R/R DLBCL in 3 L and 4 L settings including those who were resistant to or progressed after CAR-T.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"210"},"PeriodicalIF":12.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11604956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. ICARIA-MM和IKEMA研究中国际分期系统第二次修订的分配和验证

IF 12.9 1区医学

Blood Cancer Journal Pub Date : 2024-11-28 DOI: 10.1038/s41408-024-01149-w

Paul G Richardson, Aurore Perrot, Joseph Mikhael, Thomas Martin, Meral Beksac, Ivan Spicka, Marcelo Capra, Mattia D'Agostino, Pieter Sonneveld, Kamlesh Bisht, Taro Fukao, Rick Zhang, Keisuke Tada, Christina Tekle, Sandrine Macé, Zandra Klippel, Helgi van de Velde, Philippe Moreau

{"title":"Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.","authors":"Paul G Richardson, Aurore Perrot, Joseph Mikhael, Thomas Martin, Meral Beksac, Ivan Spicka, Marcelo Capra, Mattia D'Agostino, Pieter Sonneveld, Kamlesh Bisht, Taro Fukao, Rick Zhang, Keisuke Tada, Christina Tekle, Sandrine Macé, Zandra Klippel, Helgi van de Velde, Philippe Moreau","doi":"10.1038/s41408-024-01149-w","DOIUrl":"10.1038/s41408-024-01149-w","url":null,"abstract":"The International Staging System for multiple myeloma recently underwent a second revision (R2-ISS) to include gain/amplification of 1q21 and account for the additive prognostic significance of multiple high-risk features. The phase 3 ICARIA-MM (isatuximab-pomalidomide-dexamethasone vs. pomalidomide-dexamethasone) and IKEMA (isatuximab-carfilzomib-dexamethasone vs. carfilzomib-dexamethasone) studies provide large datasets for retrospectively validating the prognostic value of the R2-ISS in relapsed/refractory multiple myeloma. Of 609 pooled patients, 68 (11.2%) were reclassified as R2-ISS stage I, 136 (22.3%) as R2-ISS stage II, 204 (33.5%) as R2-ISS stage III, 55 (9.0%) as stage IV, and 146 (24.0%) \"Not classified\". Median progression-free survival was shorter among those reclassified as R2-ISS stage II (HR 1.52, 95% CI 0.979-2.358), stage III (HR 2.59, 95% CI 1.709-3.923), and stage IV (HR 3.51, 95% CI 2.124-5.784) versus stage I. Adding isatuximab led to longer progression-free survival versus doublet therapy (adjusted HR 0.544 [95% CI 0.436-0.680]), with a consistent treatment effect observed across all R2-ISS stages. This is the first study to validate the R2-ISS with novel agents, including anti-CD38 monoclonal antibodies, and to show that R2-ISS, as a prognostic scoring system, can be applied to patients with relapsed/refractory multiple myeloma.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"209"},"PeriodicalIF":12.9,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11605113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142749532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular monitoring in CML-a modern example of an old proverb. cml中的分子监测——古谚语的现代诠释。

IF 12.9 1区医学

Blood Cancer Journal Pub Date : 2024-11-28 DOI: 10.1038/s41408-024-01192-7

Jeffrey H Lipton

引用次数: 0

RSK1 dependency in FLT3-ITD acute myeloid leukemia FLT3-ITD 急性髓性白血病中的 RSK1 依赖性

IF 12.8 1区医学

Blood Cancer Journal Pub Date : 2024-11-26 DOI: 10.1038/s41408-024-01187-4

Tim Kong, Angelo B. A. Laranjeira, Christopher T. Letson, LaYow Yu, Fan He, Aarthi Jayanthan, Gerrit Los, Sandra E. Dunn, Grant A. Challen, Stephen T. Oh

{"title":"RSK1 dependency in FLT3-ITD acute myeloid leukemia","authors":"Tim Kong, Angelo B. A. Laranjeira, Christopher T. Letson, LaYow Yu, Fan He, Aarthi Jayanthan, Gerrit Los, Sandra E. Dunn, Grant A. Challen, Stephen T. Oh","doi":"10.1038/s41408-024-01187-4","DOIUrl":"https://doi.org/10.1038/s41408-024-01187-4","url":null,"abstract":"Internal tandem duplications (ITD) in fms-like tyrosine kinase 3 (FLT3) represent the most common genetic alteration in de novo acute myeloid leukemia (AML). Here, we identify ribosomal protein s6 kinase a1 (RSK1) as a core dependency in FLT3-ITD AML and unveil the existence of crucial bi-directional regulation. RSK1 perturbation resulted in marked apoptosis and abrogated phosphorylation of FLT3 and associated downstream signaling cascades in FLT3-ITD AML cell lines. Using cycloheximide, MG-132, and ubiquitination assays, we further demonstrate mechanistically that RSK1 regulates FLT3-ITD activity, and protein stability through deubiqutinase USP1, which we identify as a second dependency. Importantly, multivariate analysis revealed heightened expression of RPS6KA1 and USP1 to be associated with poor patient prognosis, and these effectors may serve as biomarkers predictive of patient survival and therapeutic response to FLT3-ITD inhibitors. Lastly, RSK1 inhibition utilizing a first-in-class RSK inhibitor, PMD-026, that is currently undergoing Phase 2 development for breast cancer, diminished leukemic disease burden in MV4-11 xenograft and syngeneic Flt3ITDTet2KO leukemia models. These findings illustrate an unconventional and promising therapeutic strategy targeting FLT3-ITD leukemia.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"19 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142713022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CAR-T cell therapy in Multiple Myeloma: current status and future challenges 多发性骨髓瘤的 CAR-T 细胞疗法：现状与未来挑战

IF 12.8 1区医学

Blood Cancer Journal Pub Date : 2024-11-26 DOI: 10.1038/s41408-024-01191-8

Dawn Swan, Deepu Madduri, Jay Hocking

引用次数: 0

Indolent nodal T follicular helper cell lymphomas—A case series 惰性结节 T 滤泡辅助细胞淋巴瘤--病例系列

IF 12.8 1区医学

Blood Cancer Journal Pub Date : 2024-11-26 DOI: 10.1038/s41408-024-01163-y

Jie Wang, Chun En Yau, Chen Ee Low, Mohamed Haniffa Bin Hasan Mohamed, Chee Leong Cheng, Jadee L. Neff, Jing Quan Lim, Soon Thye Lim, Jason Yongsheng Chan, Choon Kiat Ong, Valerie Shiwen Yang

引用次数: 0

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia. Venetoclax与三天多频地西他滨联合疗法（DEC3-VEN）用于老年或不符合强化化疗条件的新诊断急性髓性白血病患者。

IF 12.9 1区医学

Blood Cancer Journal Pub Date : 2024-11-20 DOI: 10.1038/s41408-024-01189-2

Xiaohui Suo, Xiaojun Ma, Fang Zheng, Dongmei Wang, Guanchen Bai, Liyun Zhao, Zhongjing Han, Xin Lv, Congcong Zhang, Ju Wang, Kangxin Tuo, Zhen Meng, Shan Liu, Sifeng Gao, Jilei Zhang, Zongjiu Jiao, Jiaojie Song, Ling Li, Xinxiao Lu, Linyu Yuan, Kaiqi Liu, Xingli Zhao, Yingchang Mi

引用次数: 0

Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab Ph阴性B细胞前体急性淋巴细胞白血病的前线治疗和blinatumomab的新兴作用

IF 12.8 1区医学

Blood Cancer Journal Pub Date : 2024-11-19 DOI: 10.1038/s41408-024-01179-4

Elias J. Jabbour, Hagop M. Kantarjian, Nicola Goekbuget, Bijal D. Shah, Sabina Chiaretti, Jae H. Park, Anita W. Rijneveld, Lia Gore, Shaun Fleming, Aaron C. Logan, Josep M. Ribera, Tobias F. Menne, Khalid Mezzi, Faraz Zaman, Kelly Velasco, Nicolas Boissel

{"title":"Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab","authors":"Elias J. Jabbour, Hagop M. Kantarjian, Nicola Goekbuget, Bijal D. Shah, Sabina Chiaretti, Jae H. Park, Anita W. Rijneveld, Lia Gore, Shaun Fleming, Aaron C. Logan, Josep M. Ribera, Tobias F. Menne, Khalid Mezzi, Faraz Zaman, Kelly Velasco, Nicolas Boissel","doi":"10.1038/s41408-024-01179-4","DOIUrl":"https://doi.org/10.1038/s41408-024-01179-4","url":null,"abstract":"This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome–negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell–engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens. However, these intense regimens are not tolerated by all, and high-risk patients still have inferior outcomes. Therefore, designing more effective and less toxic strategies remains key to further improving efficacy and safety outcomes. Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"38 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142670896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0